ONDANSETRON HYDROCHLORIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for ondansetron hydrochloride and what is the scope of freedom to operate?
Ondansetron hydrochloride
is the generic ingredient in six branded drugs marketed by Accord Hlthcare, Am Regent, Apotex Inc, Avet Lifesciences, Baxter Hlthcare Corp, Chartwell Molecular, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Hikma Farmaceutica, Hospira, Lannett Co Inc, Luitpold, Pliva Hrvatska Doo, Qilu Pharm Hainan, Rising, Sagent Pharms, Sandoz, Steriscience Speclts, Sun Pharm Inds (in), Teva, Wockhardt, Sun Pharm Inds Ltd, Taro Pharms Ireland, Glaxosmithkline, Amneal Pharms, Aurobindo Pharma, Pharm Assoc, Taro, Apotex, Chartwell Molecules, Chartwell Rx, Dr Reddys Labs Ltd, Glenmark Pharms Ltd, Hikma Intl Pharms, Ipca Labs Ltd, and Natco Pharma Ltd, and is included in seventy-two NDAs. Additional information is available in the individual branded drug profile pages.There are sixteen drug master file entries for ondansetron hydrochloride. Sixty-six suppliers are listed for this compound. There are two tentative approvals for this compound.
Summary for ONDANSETRON HYDROCHLORIDE
US Patents: | 0 |
Tradenames: | 6 |
Applicants: | 38 |
NDAs: | 72 |
Drug Master File Entries: | 16 |
Finished Product Suppliers / Packagers: | 66 |
Raw Ingredient (Bulk) Api Vendors: | 81 |
Clinical Trials: | 615 |
Patent Applications: | 2,135 |
What excipients (inactive ingredients) are in ONDANSETRON HYDROCHLORIDE? | ONDANSETRON HYDROCHLORIDE excipients list |
DailyMed Link: | ONDANSETRON HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for ONDANSETRON HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Yongtao Sun | Phase 4 |
King Saud Medical City | Phase 3 |
Ain Shams University | N/A |
Generic filers with tentative approvals for ONDANSETRON HYDROCHLORIDE
Applicant | Application No. | Strength | Dosage Form |
⤷ Sign Up | ⤷ Sign Up | EQ 2MG BASE/ML | INJECTABLE;INJECTION |
⤷ Sign Up | ⤷ Sign Up | EQ 2MG BASE/ML | INJECTABLE;INJECTION |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for ONDANSETRON HYDROCHLORIDE
Drug Class | Serotonin-3 Receptor Antagonist |
Mechanism of Action | Serotonin 3 Receptor Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for ONDANSETRON HYDROCHLORIDE
Paragraph IV (Patent) Challenges for ONDANSETRON HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
ZOFRAN | Oral Solution | ondansetron hydrochloride | 4 mg/5 mL | 020605 | 1 | 2004-12-20 |
US Patents and Regulatory Information for ONDANSETRON HYDROCHLORIDE
Expired US Patents for ONDANSETRON HYDROCHLORIDE
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.